JP2017523188A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523188A5
JP2017523188A5 JP2017504752A JP2017504752A JP2017523188A5 JP 2017523188 A5 JP2017523188 A5 JP 2017523188A5 JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017523188 A5 JP2017523188 A5 JP 2017523188A5
Authority
JP
Japan
Prior art keywords
dlbcl
use according
modification
amino acid
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017504752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043300 external-priority patent/WO2016019341A1/en
Publication of JP2017523188A publication Critical patent/JP2017523188A/ja
Publication of JP2017523188A5 publication Critical patent/JP2017523188A5/ja
Pending legal-status Critical Current

Links

JP2017504752A 2014-08-01 2015-07-31 Btk阻害剤を伴う治療に対するdlbclの応答を予測するためのバイオマーカー Pending JP2017523188A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462032430P 2014-08-01 2014-08-01
US62/032,430 2014-08-01
US201562119668P 2015-02-23 2015-02-23
US62/119,668 2015-02-23
US201562127484P 2015-03-03 2015-03-03
US62/127,484 2015-03-03
PCT/US2015/043300 WO2016019341A1 (en) 2014-08-01 2015-07-31 Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor

Publications (2)

Publication Number Publication Date
JP2017523188A JP2017523188A (ja) 2017-08-17
JP2017523188A5 true JP2017523188A5 (https=) 2018-09-13

Family

ID=55179406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017504752A Pending JP2017523188A (ja) 2014-08-01 2015-07-31 Btk阻害剤を伴う治療に対するdlbclの応答を予測するためのバイオマーカー

Country Status (13)

Country Link
US (1) US20160032404A1 (https=)
EP (1) EP3185870A4 (https=)
JP (1) JP2017523188A (https=)
KR (1) KR20170042614A (https=)
CN (1) CN106714804A (https=)
AU (1) AU2015296010A1 (https=)
BR (1) BR112017001677A2 (https=)
CA (1) CA2955744A1 (https=)
IL (1) IL250221A0 (https=)
MX (1) MX2017001302A (https=)
RU (1) RU2017106794A (https=)
SG (1) SG11201700774UA (https=)
WO (1) WO2016019341A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
WO2016071770A2 (en) * 2014-11-05 2016-05-12 Janssen Pharmaceutica Nv Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same
HUE061448T2 (hu) 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
RS64653B1 (sr) 2015-04-06 2023-10-31 Janssen Pharmaceutica Nv Kompozicije koje sadrže ibrutinib
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
ES2836222T3 (es) 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US11085039B2 (en) 2016-12-12 2021-08-10 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays
CN110268108B (zh) * 2016-12-12 2022-09-06 埃克切拉生物科学公司 用于使用微毛细管阵列进行筛选的方法和系统
EP3562796B1 (en) 2016-12-30 2023-04-19 Xcella Biosciences, Inc. Multi-stage sample recovery system
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
AU2018282127B2 (en) 2017-06-08 2023-11-16 Enlivex Therapeutics Rdo Ltd Therapeutic apoptotic cells for cancer therapy
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
EA202190045A1 (ru) 2018-06-15 2021-03-17 Янссен Фармацевтика Нв Составы/композиции, содержащие ибрутиниб
GB2577909B (en) * 2018-10-10 2020-11-18 Symetrica Ltd Gamma-ray spectrum classification
US20200171034A1 (en) * 2018-11-30 2020-06-04 Janssen Biotech, Inc. Methods Of Treating Follicular Lymphoma
ES3039910T3 (en) 2018-12-06 2025-10-27 Xcella Biosciences Inc Lateral loading of microcapillary arrays
WO2021087044A1 (en) * 2019-10-30 2021-05-06 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
CN116848267A (zh) * 2021-02-03 2023-10-03 柯瑞斯公司 非美诺司他治疗的生物标志物
JP2024526241A (ja) * 2021-06-30 2024-07-17 ヤンセン ファーマシューティカ エヌ.ベー. ブルトン型チロシンキナーゼの阻害剤及びその使用方法
WO2023275330A1 (en) * 2021-06-30 2023-01-05 Janssen Pharmaceutica Nv Treatments for diffuse large b-cell lymphoma
JP7423090B2 (ja) * 2022-04-07 2024-01-29 学校法人藤田学園 不明熱患者のb細胞リンパ腫診断補助キットおよび情報提供方法
WO2025080543A1 (en) * 2023-10-09 2025-04-17 Bristol-Myers Squibb Company Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
JP7696987B1 (ja) * 2023-12-22 2025-06-23 東洋鋼鈑株式会社 遺伝子変異を検出する方法
JP7698850B1 (ja) 2023-12-22 2025-06-26 東洋鋼鈑株式会社 遺伝子変異評価用キット

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107898791A (zh) * 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
US20130102477A1 (en) * 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
WO2013059738A2 (en) * 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
AR088570A1 (es) * 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
JO3754B1 (ar) * 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
CN104704129A (zh) * 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
JP2016505012A (ja) * 2013-01-10 2016-02-18 ニンバス アイリス, インコーポレイテッド Irak阻害剤およびその使用

Similar Documents

Publication Publication Date Title
JP2017523188A5 (https=)
RU2017106794A (ru) Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк
CY1121873T1 (el) Θεραπευτικη αντιμετωπιση του καρκινου
EA201890006A1 (ru) Применение экзосом для лечения болезни
EA201992063A1 (ru) СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
MY185845A (en) Icos binding proteins
JP2014523751A5 (https=)
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
EP2568996A4 (en) INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF PHENYLALANYL BETA-TRNA SYNTHETASES
WO2017027571A8 (en) Mechanism of resistance to bet bromodomain inhibitors
WO2017116817A3 (en) Testing of medicinal drugs and drug combinations
MX2015016304A (es) Proteinas de union al antigeno del receptor de oncostatina m.
EA201790504A1 (ru) Монослой мононуклеарных клеток периферической крови или клеток костного мозга и его применение
JP2017506259A5 (https=)
BR112017022553A2 (pt) métodos e materiais para matar células infectadas por hiv
WO2018026969A3 (en) Plazomicin antibodies and methods of use
TWD195924S (zh) 寶石
CN109562093A (zh) 含peitc的药物组合物及其在癌症治疗中的应用
SG10201903424RA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
CO2019002853A2 (es) Composiciones de tesofensina
WO2015168607A3 (en) Ceacam5 peptides for crohn's disease
Ling et al. Re: Gut microbiota depletion from early adolescence in mice: Implications for brain and behavior
WO2016096640A3 (en) Anti-cxcl12 antibody molecules and their uses
WO2016090001A9 (en) Deep intronic mutation found adult polyglucosan body disease and uses thereof
PAUL An In-depth Description and Detailed Analysis of Implementing Alternative Methods of Financing Software